Emergent Biosolutions, Inc. (EBS)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 900
- Market Cap
- $235M
About Emergent Biosolutions, Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
SentiSense also tracks daily options readings for Emergent Biosolutions, Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Emergent Biosolutions, Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.